PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2021/46 - ArchiMed / Cresbard Invest
Acquiring
ArchiMed SAS
Description
It is a private equity firm that operates as a strategic and financial partner for European and North American small and medium companies in targeted healthcare segments, including pharmaceuticals, medical devices and technology, IT (information technologies). Consumer health and health.
Acquired
Cresbard Invest, S.L
Description
It is a holding company and the sole shareholder of SuanFarma. In Portugal, SuanFarma is active through its subsidiaries, Lusosuan S.G.P.S. and Companhia Industrial Produtora de Antibióticos SA, in the following business areas: (i) in the provision of exploration and production services, (ii) in the development, manufacture and supply of intermediates and active pharmaceutical ingredients for medicines intended for human and veterinary use, (iii) intermediaries for medicines intended for human and veterinary use; and (iv) in the distribution of nutraceutical ingredients.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Applicable legislation
Art. 37(1)(a) (Law 19)
Notification thresholds
Market Share threshold
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description
The notified concentration consists of the acquisition of sole control over Cresbard Invest, S.L by ArchiMed SAS.
Timeline
2021-10-26
The Board of the Competition Authority issued a non-opposition decision to the merger 46/2021 - ArchiMed / Cresbard Invest.
2021-09-30
ArchiMed notifies the acquisition of sole control over Cresbard Invest.
Click here to see your activities